{
  "DOI": "10.1007/s10689-020-00207-z",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-020-00207-z",
  "alternative-id": [
    "207"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 1,
      "value": "28 September 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "DGE has received travel grants from AstraZeneca."
    },
    {
      "label": "Free to read",
      "name": "free",
      "value": "This content has been made available to all."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Evans",
      "given": "D. Gareth",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Woodward",
      "given": "Emma R.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        9,
        28
      ]
    ],
    "date-time": "2020-09-28T03:26:21Z",
    "timestamp": 1601263581000
  },
  "deposited": {
    "date-parts": [
      [
        2021,
        9,
        28
      ]
    ],
    "date-time": "2021-09-28T00:41:51Z",
    "timestamp": 1632789711000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        5,
        1
      ]
    ],
    "date-time": "2024-05-01T00:48:49Z",
    "timestamp": 1714524529340
  },
  "is-referenced-by-count": 8,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2020,
        9,
        28
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2021,
          1
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            9,
            28
          ]
        ],
        "date-time": "2020-09-28T00:00:00Z",
        "timestamp": 1601251200000
      }
    },
    {
      "URL": "https://www.springer.com/tdm",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            9,
            28
          ]
        ],
        "date-time": "2020-09-28T00:00:00Z",
        "timestamp": 1601251200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-020-00207-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-020-00207-z/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-020-00207-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1-7",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2020,
        9,
        28
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        9,
        28
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2021,
        1
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1126/science.1978757",
      "author": "D Malkin",
      "doi-asserted-by": "crossref",
      "first-page": "1233",
      "journal-title": "Science",
      "key": "207_CR1",
      "unstructured": "Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238",
      "volume": "250",
      "year": "1990"
    },
    {
      "DOI": "10.7326/0003-4819-71-4-747",
      "author": "FP Li",
      "doi-asserted-by": "crossref",
      "first-page": "747",
      "journal-title": "Ann Intern Med",
      "key": "207_CR2",
      "unstructured": "Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752",
      "volume": "71",
      "year": "1969"
    },
    {
      "DOI": "10.1016/0306-9877(79)90059-8",
      "author": "HT Lynch",
      "doi-asserted-by": "crossref",
      "first-page": "15",
      "journal-title": "Med Hypotheses",
      "key": "207_CR3",
      "unstructured": "Lynch HT, Guirgis HA (1979) Childhood cancer and the SBLA syndrome. Med Hypotheses 5:15–22",
      "volume": "5",
      "year": "1979"
    },
    {
      "author": "FP Li",
      "first-page": "5358",
      "journal-title": "Cancer Res",
      "key": "207_CR4",
      "unstructured": "Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362",
      "volume": "48",
      "year": "1988"
    },
    {
      "DOI": "10.1200/JCO.2014.59.5728",
      "author": "G Bougeard",
      "doi-asserted-by": "publisher",
      "first-page": "2345",
      "issue": "21",
      "journal-title": "J Clin Oncol",
      "key": "207_CR5",
      "unstructured": "Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio PR, Bressac-de Paillerets B, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting li-fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345–2352. https://doi.org/10.1200/JCO.2014.59.5728",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1002/pbc.24223",
      "author": "S Magnusson",
      "doi-asserted-by": "crossref",
      "first-page": "846",
      "journal-title": "Pediatr Blood Cancer",
      "key": "207_CR6",
      "unstructured": "Magnusson S, Gisselsson D, Wiebe T, Kristoffersson U, Borg Å, Olsson H (2012) Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey. Pediatr Blood Cancer 59:846–853",
      "volume": "59",
      "year": "2012"
    },
    {
      "DOI": "10.1002/cncr.28507",
      "author": "S Hettmer",
      "doi-asserted-by": "crossref",
      "first-page": "1068",
      "journal-title": "Cancer",
      "key": "207_CR7",
      "unstructured": "Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L et al (2014) Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120:1068–1075",
      "volume": "120",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2009.26.8169",
      "author": "U Tabori",
      "doi-asserted-by": "crossref",
      "first-page": "1995",
      "journal-title": "J Clin Oncol",
      "key": "207_CR8",
      "unstructured": "Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N et al (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995–2001",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1038/sj.bjc.6605606",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "1091",
      "journal-title": "Br J Cancer",
      "key": "207_CR9",
      "unstructured": "Evans DG, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F (2010) Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 102:1091–1098",
      "volume": "102",
      "year": "2010"
    },
    {
      "DOI": "10.1200/JCO.2008.16.6959",
      "author": "KD Gonzalez",
      "doi-asserted-by": "crossref",
      "first-page": "1250",
      "journal-title": "J Clin Oncol",
      "key": "207_CR10",
      "unstructured": "Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250–1256",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1136/jmg.2009.073429",
      "author": "MW Ruijs",
      "doi-asserted-by": "crossref",
      "first-page": "421",
      "journal-title": "J Med Genet",
      "key": "207_CR11",
      "unstructured": "Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB et al (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421–428",
      "volume": "47",
      "year": "2010"
    },
    {
      "DOI": "10.1038/s41431-020-0638-4",
      "author": "T Frebourg",
      "doi-asserted-by": "publisher",
      "journal-title": "Eur J Hum Genet",
      "key": "207_CR12",
      "unstructured": "Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, European Reference Network GENTURIS (2020) Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. https://doi.org/10.1038/s41431-020-0638-4",
      "year": "2020"
    },
    {
      "DOI": "10.1136/jmedgenet-2020-106876",
      "author": "H Hanson",
      "doi-asserted-by": "publisher",
      "journal-title": "J Med Genet",
      "key": "207_CR13",
      "unstructured": "Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, Izatt L, Sohaib A, Tischkowitz M, Evans DG, Consensus Group Members (2020) UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. https://doi.org/10.1136/jmedgenet-2020-106876",
      "year": "2020"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-17-0408",
      "author": "CP Kratz",
      "doi-asserted-by": "crossref",
      "first-page": "e38",
      "journal-title": "Clin Cancer Res",
      "key": "207_CR14",
      "unstructured": "Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC et al (2018) Cancer screening recommendations for individuals with li-fraumeni syndrome. Clin Cancer Res 23:e38–e45",
      "volume": "23",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1470-2045(16)30249-2",
      "author": "A Villani",
      "doi-asserted-by": "crossref",
      "first-page": "1295",
      "journal-title": "Lancet Oncol",
      "key": "207_CR15",
      "unstructured": "Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17:1295–1305",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1002/humu.23656",
      "author": "C Fortuno",
      "doi-asserted-by": "crossref",
      "first-page": "1764",
      "journal-title": "Hum Mutat",
      "key": "207_CR16",
      "unstructured": "Fortuno C, James PA, Spurdle AB (2018) Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat 39:1764–1773",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s10689-018-00118-0",
      "author": "JJ Bakhuizen",
      "doi-asserted-by": "crossref",
      "first-page": "273",
      "journal-title": "Fam Cancer",
      "key": "207_CR17",
      "unstructured": "Bakhuizen JJ, Hogervorst FB, Velthuizen ME, Ruijs MW, van Engelen K, van Os TA, Gille JJ, Collée M, van den Ouweland AM, van Asperen CJ, Kets CM, Mensenkamp AR, Leter EM, Blok MJ, de Jong MM, Ausems MG (2019) TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort. Fam Cancer 18:273–280",
      "volume": "18",
      "year": "2019"
    },
    {
      "author": "D Sidransky",
      "first-page": "2984",
      "journal-title": "Cancer Res",
      "key": "207_CR18",
      "unstructured": "Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986",
      "volume": "52",
      "year": "1992"
    },
    {
      "DOI": "10.1038/bjc.1997.205",
      "author": "M Zelada-Hedman",
      "doi-asserted-by": "crossref",
      "first-page": "1201",
      "journal-title": "Br J Cancer",
      "key": "207_CR19",
      "unstructured": "Zelada-Hedman M, Børresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A (1997) Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 75:1201–1204",
      "volume": "75",
      "year": "1997"
    },
    {
      "key": "207_CR20",
      "unstructured": "Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno CL (2020) Breast cancer risk genes: association analysis of rare coding variants in 34 genes in 60,466 cases and 53,461 controls. N Engl J Med. In press"
    },
    {
      "DOI": "10.1002/humu.24053",
      "author": "SN Hart",
      "doi-asserted-by": "publisher",
      "first-page": "e1",
      "journal-title": "Hum Mutat",
      "key": "207_CR21",
      "unstructured": "Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS (2020) Mutation prevalence tables for hereditary cancer derived from multigene panel testing. Hum Mutat 41:e1–e6. https://doi.org/10.1002/humu.24053",
      "volume": "41",
      "year": "2020"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-18-1102",
      "author": "C Petridis",
      "doi-asserted-by": "crossref",
      "first-page": "1162",
      "journal-title": "Cancer Epidemiol Biomarkers Prev",
      "key": "207_CR22",
      "unstructured": "Petridis C, Arora I, Shah V, Moss CL, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ (2019) Frequency of pathogenic germline variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in sporadic lobular breast cancer. Cancer Epidemiol Biomarkers Prev 28:1162–1168",
      "volume": "28",
      "year": "2019"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105188",
      "author": "A Taylor",
      "doi-asserted-by": "crossref",
      "first-page": "372",
      "journal-title": "J Med Genet",
      "key": "207_CR23",
      "unstructured": "Taylor A, Brady AF, Frayling IM, Hanson H, Tischkowitz M, Turnbull C, Side L, UK Cancer Genetics Group (UK-CGG) (2018) Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. J Med Genet 55:372–377",
      "volume": "55",
      "year": "2018"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "author": "S Richards",
      "doi-asserted-by": "crossref",
      "first-page": "405",
      "journal-title": "Genet Med.",
      "key": "207_CR24",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17:405–424",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1101/2020.04.25.20078931",
      "doi-asserted-by": "crossref",
      "key": "207_CR25",
      "unstructured": "Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC et al (2020) Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat in press"
    },
    {
      "DOI": "10.1073/pnas.1431692100",
      "author": "S Kato",
      "doi-asserted-by": "crossref",
      "first-page": "8424",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "207_CR26",
      "unstructured": "Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein byhigh-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424–8429",
      "volume": "100",
      "year": "2003"
    },
    {
      "DOI": "10.1093/hmg/ddx106",
      "author": "Y Zerdoumi",
      "doi-asserted-by": "crossref",
      "first-page": "2591",
      "journal-title": "Hum Mol Genet",
      "key": "207_CR27",
      "unstructured": "Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, Tournier I (2017) Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet 26:2591–2602",
      "volume": "26",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41588-018-0204-y",
      "author": "AO Giacomelli",
      "doi-asserted-by": "crossref",
      "first-page": "1381",
      "journal-title": "Nat Genet",
      "key": "207_CR28",
      "unstructured": "Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J et al (2018) Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 50:1381–1387",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.molcel.2018.06.012",
      "author": "E Kotler",
      "doi-asserted-by": "crossref",
      "first-page": "178",
      "journal-title": "Mol Cell",
      "key": "207_CR29",
      "unstructured": "Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A et al (2018) A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell 71:178–90",
      "volume": "71",
      "year": "2018"
    },
    {
      "DOI": "10.1002/humu.23673",
      "author": "KC de Andrade",
      "doi-asserted-by": "crossref",
      "first-page": "97",
      "journal-title": "Hum Mutat",
      "key": "207_CR30",
      "unstructured": "de Andrade KC, Frone MN, Wegman-Ostrosky T, Khincha PP, Kim J, Amadou A et al (2019) Variable population prevalence estimates of germline TP53 variants: a gnomAD-based analysis. Hum Mutat 40:97–105",
      "volume": "40",
      "year": "2019"
    },
    {
      "DOI": "10.1002/humu.23750",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "828",
      "journal-title": "Hum Mutat",
      "key": "207_CR31",
      "unstructured": "Evans DG, Turnbull C, Woodward ER (2019) Concern regarding classification of germline TP53 variants as likely pathogenic. Hum Mutat 40:828–831",
      "volume": "40",
      "year": "2019"
    },
    {
      "DOI": "10.1016/S0140-6736(03)12856-5",
      "author": "F Lalloo",
      "doi-asserted-by": "crossref",
      "first-page": "1101",
      "journal-title": "Lancet",
      "key": "207_CR32",
      "unstructured": "Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans D, Onset Breast Cancer Study Group (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101–1102",
      "volume": "361",
      "year": "2003"
    },
    {
      "DOI": "10.1001/jamaoncol.2015.0197",
      "author": "MB Yurgelun",
      "doi-asserted-by": "crossref",
      "first-page": "214",
      "journal-title": "JAMA Oncol",
      "key": "207_CR33",
      "unstructured": "Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM et al (2015) Germline TP53 mutations in patients with early-onset colorectal cancer in the colon cancer family registry. JAMA Oncol 1:214–221",
      "volume": "1",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41436-019-0598-7",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "53",
      "journal-title": "Genet Med",
      "key": "207_CR34",
      "unstructured": "Evans DG, Hartley CL, Smith PT, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Stapleton E, Freeman SR, Kellett M, Halliday D, Parry A, Gair JJ, Axon P, Laitt R, Thomas O, Afridi SK, Obholzer R, English Specialist NF research group, Duff C, Stivaros SM, Vassallo G, Harkness EF, Smith MJ (2020) Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med 22:53–59",
      "volume": "22",
      "year": "2020"
    },
    {
      "DOI": "10.1186/s13058-019-1193-1",
      "author": "F Batalini",
      "doi-asserted-by": "crossref",
      "first-page": "107",
      "journal-title": "Breast Cancer Res",
      "key": "207_CR35",
      "unstructured": "Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM (2019) Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res 21:107",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1002/humu.23653",
      "author": "K Weber-Lassalle",
      "doi-asserted-by": "crossref",
      "first-page": "2040",
      "journal-title": "Hum Mutat",
      "key": "207_CR36",
      "unstructured": "Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F et al (2018) Diagnosis of li-fraumeni syndrome: differentiating TP53 germline mutations from clonal hematopoiesis: results of the observational AGO-TR1 trial. Hum Mutat 39:2040–2046",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1038/gim.2017.196",
      "author": "JN Weitzel",
      "doi-asserted-by": "crossref",
      "first-page": "809",
      "journal-title": "Genet Med",
      "key": "207_CR37",
      "unstructured": "Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR et al (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809–816",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1097/MOH.0000000000000509",
      "author": "S Chen",
      "doi-asserted-by": "crossref",
      "first-page": "235",
      "journal-title": "Curr Opin Hematol",
      "key": "207_CR38",
      "unstructured": "Chen S, Liu Y (2019) p53 involvement in clonal hematopoiesis of indeterminate potential. Curr Opin Hematol 4:235–240",
      "volume": "4",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.jmoldx.2019.12.003",
      "author": "JL Mester",
      "doi-asserted-by": "crossref",
      "first-page": "396",
      "journal-title": "J Mol Diagn",
      "key": "207_CR39",
      "unstructured": "Mester JL, Jackson SA, Postula K, Stettner A, Solomon S, Bissonnette J, Murphy PD, Klein RT, Hruska KS (2020) Apparently heterozygous TP53 pathogenic variants may be blood limited in patients undergoing hereditary cancer panel testing. J Mol Diagn 22:396–404",
      "volume": "22",
      "year": "2020"
    },
    {
      "key": "207_CR40",
      "unstructured": "https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive#heading-One Accessed 28 Aug 2020"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-19-0728",
      "author": "SJ Shin",
      "doi-asserted-by": "crossref",
      "first-page": "354",
      "journal-title": "Cancer Res",
      "key": "207_CR41",
      "unstructured": "Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI et al (2020) Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts. Cancer Res 80:354–360",
      "volume": "80",
      "year": "2020"
    },
    {
      "DOI": "10.3390/cancers12020378",
      "author": "Z Hyder",
      "doi-asserted-by": "crossref",
      "first-page": "378",
      "journal-title": "Cancers (Basel)",
      "key": "207_CR42",
      "unstructured": "Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Evans DG (2020) Risk of contralateral breast cancer in women with and without pathogenic variants in BRCA1, BRCA2, and tp53 genes in women with very early-onset (\u003c36 Years) breast cancer. Cancers (Basel) 12:378",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.1054/bjoc.2000.1167",
      "author": "A Chompret",
      "doi-asserted-by": "crossref",
      "first-page": "1932",
      "journal-title": "Br J Cancer",
      "key": "207_CR43",
      "unstructured": "Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932–1937",
      "volume": "82",
      "year": "2000"
    },
    {
      "DOI": "10.1002/cncr.30248",
      "author": "PL Mai",
      "doi-asserted-by": "crossref",
      "first-page": "3673",
      "journal-title": "Cancer",
      "key": "207_CR44",
      "unstructured": "Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122:3673–3681",
      "volume": "122",
      "year": "2016"
    },
    {
      "DOI": "10.1097/CCO.0000000000000423",
      "author": "A Amadou",
      "doi-asserted-by": "crossref",
      "first-page": "23",
      "journal-title": "Curr Opin Oncol",
      "key": "207_CR45",
      "unstructured": "Amadou A, Waddington Achatz MI, Hainaut P (2018) Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol 30:23–29",
      "volume": "30",
      "year": "2018"
    },
    {
      "DOI": "10.1136/jmg.2004.030551",
      "author": "BC Figueiredo",
      "doi-asserted-by": "crossref",
      "first-page": "91",
      "journal-title": "J Med Genet",
      "key": "207_CR46",
      "unstructured": "Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W et al (2006) Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43:91–96",
      "volume": "43",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.canlet.2005.12.039",
      "author": "MI Achatz",
      "doi-asserted-by": "crossref",
      "first-page": "96",
      "journal-title": "Cancer Lett",
      "key": "207_CR47",
      "unstructured": "Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM et al (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245:96–102",
      "volume": "245",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.canlet.2007.10.044",
      "author": "EI Palmero",
      "doi-asserted-by": "crossref",
      "first-page": "21",
      "journal-title": "Cancer Lett",
      "key": "207_CR48",
      "unstructured": "Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G et al (2008) Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261:21–25",
      "volume": "261",
      "year": "2008"
    },
    {
      "DOI": "10.1590/1678-4685-gmb-2014-0343",
      "author": "KC Andrade",
      "doi-asserted-by": "crossref",
      "first-page": "199",
      "journal-title": "Genet Mol Biol",
      "key": "207_CR49",
      "unstructured": "Andrade KC, Santiago KM, Fortes FP, Mambelli LI, Nóbrega AF, Achatz MI (2016) Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p. R337H mutation. Genet Mol Biol 39:199–202",
      "volume": "39",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.ejca.2018.06.011",
      "author": "E Kasper",
      "doi-asserted-by": "crossref",
      "first-page": "254",
      "journal-title": "Eur J Cancer",
      "key": "207_CR50",
      "unstructured": "Kasper E, Angot E, Colasse E, Nicol L, Sabourin JC, Adriouch S et al (2018) Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer 101:254–262",
      "volume": "101",
      "year": "2018"
    },
    {
      "DOI": "10.1136/jmg.2005.036319",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "289",
      "journal-title": "J Med Genet",
      "key": "207_CR51",
      "unstructured": "Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289–294",
      "volume": "43",
      "year": "2006"
    },
    {
      "DOI": "10.1200/JCO.2009.27.2112",
      "author": "CR Lammens",
      "doi-asserted-by": "crossref",
      "first-page": "3008",
      "issue": "18",
      "journal-title": "J Clin Oncol",
      "key": "207_CR52",
      "unstructured": "Lammens CR, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, Vriends AH, Ruijs MW, van Os TA, Spruijt L, Gómez García EB, Kluijt I, Nagtegaal T, Verhoef S, Bleiker EM (2010) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008–3014",
      "volume": "28",
      "year": "2010"
    },
    {
      "DOI": "10.1002/humu.20880",
      "author": "SE Plon",
      "doi-asserted-by": "crossref",
      "first-page": "1282",
      "journal-title": "Hum Mutat",
      "key": "207_CR53",
      "unstructured": "Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV, IARC Unclassified Genetic Variants Working Group (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291",
      "volume": "29",
      "year": "2008"
    }
  ],
  "reference-count": 53,
  "references-count": 53,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-020-00207-z"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "20"
}